Evidence map›Paper›PMID 38361740›Full record

ArticleJTO clinical and research reports2024

Long-Term Efficacy of Immune Checkpoint Inhibitor for Squamous Cell Carcinoma Lesion Transformed From

Shota Takahashi, Yuki Sato, Yoshiharu Sato, Ryosuke Hirabayashi, Shigeo Hara, Yutaka Takahashi, Keisuke Tomii

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in JTO clinical and research reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 10 countries.

Shota TakahashiDepartment of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Japan.
Yuki SatoDepartment of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Japan.
Yoshiharu SatoDNA Chip Research Inc., Tokyo, Japan.
Ryosuke HirabayashiDepartment of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Japan.
Shigeo HaraDepartment of Pathology, Kobe City Medical Center General Hospital, Kobe, Japan.
Yutaka TakahashiDepartment of Thoracic Surgery, Kobe City Medical Center General Hospital, Kobe, Japan.
Keisuke TomiiDepartment of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Japan.
Kobe City Medical Center General Hospital · JPOno Pharmaceutical (United Kingdom) · GBShionogi (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Histologic transformation is one of the mechanisms of resistance to EGFR tyrosine kinase inhibitor in patients with NSCLC with

Indexed as

Acquired resistanceCase reportHistologic transformationImmune checkpoint inhibitorOsimertinib

Identifiers

PMID38361740
PMCPMC10867436
OpenAlexW4391042323

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.